Aurinia Pharmaceuticals (AUPH)
Markets LUPKYNIS for lupus nephritis and develops additional autoimmune therapies.
$16.29
Pre-market−0.01 (−0.06%)
At close$16.30(+1.56%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions292 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 58.88% | 78.34M shares | |
| Insiders12 holders · as of Aug 25, 2026 | 3.18% | 4.23M shares | |
| Strategic holders1 holder · as of Feb 13, 2020 | 2.21% | 2.94M shares | |
| Otherremainder | ≈ 35.73% | 47.54M shares |
133.05M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Jun 30, 2026
292 holders · 78.34M shares · 50 new positions · 155 increased · 81 reduced · 29 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Tang Capital Management LLC | 13.04M | 9.80% | +814.6K | Aug 14, 2026 |
| BlackRock, Inc. | 8.19M | 6.16% | +347.6K | Aug 7, 2026 |
| Goldman Sachs Group Inc | 5.62M | 4.22% | +4.19M | Aug 14, 2026 |
| Nea Management Company, LLC | 3.97M | 2.98% | 0 | Aug 14, 2026 |
| Two Sigma Investments, LP | 3.47M | 2.61% | +38.8K | Aug 14, 2026 |
| Arrowstreet Capital, Limited Partnership | 3.26M | 2.45% | −20.3K | Aug 13, 2026 |
| State Street Corp | 2.59M | 1.95% | +62.5K | Aug 7, 2026 |
| Morgan Stanley | 2.31M | 1.73% | +75.7K | Aug 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Tang Capital Management, LLCincl. Tang Capital Partners Iv, Inc, Kevin Tang +3 more | 10.00% | 13.04M | 13D | Jun 4, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | Stephen P. Robertsonofficer: Chief Legal Officer | Sale | 20,975 | $16.97 | 600,787 |
| May 29, 2026 | Kevin Tangdirector, 10 percent owner, officer: Chief Executive Officer | Purchase · 2 lots | 264,981 | $15.31 | 12,494,481 |
| Jun 1, 2026 | Kevin Tangdirector, 10 percent owner, officer: Chief Executive Officer | Purchase · 2 lots | 343,620 | $15.28 | 12,838,101 |
| Jun 2, 2026 | Kevin Tangdirector, 10 percent owner, officer: Chief Executive Officer | Purchase | 206,005 | $15.28 | 13,044,106 |
| Feb 27, 2026 | Kevin Tangdirector | Purchase · 3 lots | 516,439 | $13.99 | 11,845,939 |
| Mar 2, 2026 | Kevin Tangdirector | Purchase · 2 lots | 199,353 | $14.26 | 12,045,292 |
| Mar 3, 2026 | Kevin Tangdirector | Purchase | 184,208 | $14.22 | 12,229,500 |
CongressHouse and Senate disclosures
Not reported.